Form 4: Deep Track Funds Boost LBRX Stake with $40M Investment

Deep Track Biotechnology Master Fund and affiliates significantly increased their beneficial ownership in LB Pharmaceuticals Inc. through a conversion of preferred stock and direct common stock purchases.

Summary

• Deep Track Biotechnology Master Fund, Ltd. and its affiliates, Deep Track Capital, LP, and David Kroin, reported changes in beneficial ownership of LB Pharmaceuticals Inc. (LBRX).
• On September 12, 2025, 16,666,667 shares of Series C Preferred Stock held by Deep Track Biotechnology Master Fund, Ltd. were converted into 686,138 shares of Common Stock.
• Concurrently, Deep Track Biotechnology Master Fund, Ltd. directly purchased 2,000,000 shares of Common Stock at $15 per share, totaling $30,000,000.
• Deep Track Special Opportunities Fund, LP, an affiliate, purchased 666,666 shares of Common Stock at $15 per share, totaling $9,999,990.
• Following these transactions, Deep Track Biotechnology Master Fund, Ltd. directly holds 2,686,138 shares of Common Stock.
• Deep Track Special Opportunities Fund, LP indirectly holds 666,666 shares of Common Stock.
• The reporting persons are identified as 10% Owners and Directors of LB Pharmaceuticals Inc.

Sentiment

Score: 8

Explanation: The filing reports significant insider buying and conversion of preferred stock to common stock by a major institutional investor and director, indicating strong confidence and a positive outlook for the company's future.

Positives

• Significant investment by a major institutional shareholder and director, indicating strong confidence in the company's future prospects.
• Deep Track Biotechnology Master Fund, Ltd. directly acquired 2,000,000 shares of common stock at $15 per share, representing a $30 million investment.
• Deep Track Special Opportunities Fund, LP acquired 666,666 shares of common stock at $15 per share, representing a nearly $10 million investment.
• The conversion of Series C Preferred Stock into common stock suggests a transition to a publicly traded equity structure, often associated with an IPO.

Risks

• Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of shares held by the funds except to the extent of their respective pecuniary interests, which is a standard legal disclaimer but highlights the indirect nature of some ownership.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the significant investment by a 10% owner and director suggests a positive long-term view of the company's prospects and potential for future growth.

Management Comments

• Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. and Deep Track Special Opportunities Fund, LP.
• Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. and Deep Track Special Opportunities Fund, LP.
• Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Industry Context

This Form 4 indicates a significant insider purchase and conversion of preferred stock into common stock, which is generally viewed positively by the market as it signals confidence from a major institutional investor and director. Such transactions are common in the biotechnology sector, especially around initial public offerings (IPOs) or significant financing rounds, as investors convert prior investments into publicly traded equity.

Related Party Transactions

• The transactions involve Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, Deep Track Capital, LP, and David Kroin, all of whom are related parties as 10% owners and directors of LB Pharmaceuticals Inc. The purchases of common stock at $15 per share are related party transactions.

Stakeholder Impact

• Shareholders: Increased confidence due to significant insider investment, potentially signaling positive future performance and alignment of interests.
• Company: Strengthened capital base through the equity purchases, providing resources for operations and strategic initiatives.

Key Dates

Recommendation

The significant insider purchases by Deep Track Biotechnology Master Fund, Ltd. and its affiliates, including a director, at a price of $15 per share, signals strong conviction in LB Pharmaceuticals Inc.'s valuation and future prospects. This type of insider activity is often interpreted as a bullish indicator by seasoned investors, suggesting that those with the most intimate knowledge of the company believe the stock is undervalued or poised for growth.

Keywords

LB Pharmaceuticals, LBRX, Deep Track Biotechnology Master Fund, Deep Track Capital, David Kroin, Insider Trading, Form 4, Beneficial Ownership, Common Stock, Preferred Stock Conversion, Equity Purchase, Biotechnology